Skip to main content
PMC home page
Brazilian Journal of Microbiology logoLink to Brazilian Journal of Microbiology
. 2016 Jul 7;47(4):793–799. doi: 10.1016/j.bjm.2016.06.006

Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini review

Aícha Daniela Ribas e Ribas a, Pierri Spolti b, Emerson Medeiros Del Ponte b, Katarzyna Zawada Donato c, Henri Schrekker c, Alexandre Meneghello Fuentefria a,⁎
PMCID: PMC5052333  PMID: 27544394

Abstract

Triazole fungicides are used broadly for the control of infectious diseases of both humans and plants. The surge in resistance to triazoles among pathogenic populations is an emergent issue both in agriculture and medicine. The non-rational use of fungicides with site-specific modes of action, such as the triazoles, may increase the risk of antifungal resistance development. In the medical field, the surge of resistant fungal isolates has been related to the intensive and recurrent therapeutic use of a limited number of triazoles for the treatment and prophylaxis of many mycoses. Similarities in the mode of action of triazole fungicides used in these two fields may lead to cross-resistance, thus expanding the spectrum of resistance to multiple fungicides and contributing to the perpetuation of resistant strains in the environment. The emergence of fungicide-resistant isolates of human pathogens has been related to the exposure to fungicides used in agroecosystems. Examples include species of cosmopolitan occurrence, such as Fusarium and Aspergillus, which cause diseases in both plants and humans. This review summarizes the information about the most important triazole fungicides that are largely used in human clinical therapy and agriculture. We aim to discuss the issues related to fungicide resistance and the recommended strategies for preventing the emergence of triazole-resistant fungal populations capable of spreading across environments.

Keywords: Cross-resistance, Emerging fungal pathogens, Fungicide sensitivity, Agriculture, Medicine

Introduction

Fungicides are a key component in human therapy and the control of plant diseases caused by fungi that threaten human health and crop production.1, 2, 3, 4, 5 Among the several types of fungicides, the azole group (triazole and imidazole derivatives) was first introduced in the 1970s.3 Since then, azoles, especially the triazoles, have been widely used for the control of fungal diseases of several plants and human mycoses.6, 7, 8 As opposed to other systemic fungicides, the specific site of action of triazoles is an inherent advantage that has led to improved control efficacy of the target fungus.9, 10 However, experience has shown that these compounds are prone to resistance in the pathogenic population, especially without the following of recommended practices that are aimed at prolonging the effectiveness of these fungicides.9, 11, 12

In this context, the efficacy of triazole fungicides can be affected due to cross-resistance or when an isolate develops resistance to all fungicides in a chemical group.13, 14 Some authors have also suggested that cross- and multidrug-resistance may be driving forces in the development of resistance in fungi that are at the interfaces of agroecosystem, domestic, and hospital environments.15, 16 For instance, emerging fungi in clinical environments include saprophytic or plant pathogenic fungi that have previously exposed to triazole fungicides and end up spreading into the environment and infecting humans.6, 17, 18, 19

In this mini review, we summarize key aspects of the triazoles for therapeutic use and discuss the possible link between triazole-resistant clinical isolates and the widespread use of triazole fungicides for the control of fungal diseases, which would have a major impact in agriculture.

Basic aspects and therapeutic use of triazoles

The azole fungicides are of synthetic origin and are characterized by the presence of an aromatic five-membered heterocycle. These include triazoles (two carbon atoms and three nitrogen atoms), imidazoles (three carbon atoms and two nitrogen atoms), and thiazoles (three carbon atoms, one nitrogen atom and one sulfur atom).20 The characteristics of the azole rings, which are distinguished by the number of nitrogen and sulfur atoms, change the physical and chemical properties, toxicity, and therapeutic efficacies of these compounds.21 Therefore, the addition of different substitutes to the pristine 1,2,4-triazole molecule influences its fungicide or fungistatic effect.

Triazoles affect the biosynthesis of ergosterol, a fundamental component of the fungal cell plasma membrane.22 The main target of antifungal azole drugs is lanosterol 14-α demethylase (Erg11 protein), a cytochrome P450 enzyme that is involved in the conversion of lanosterol to 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol. The azole agents link to this enzyme using the aromatic five-membered heterocycle and thereby inhibit the cytochrome P450 catalytic activity.9, 23 The absence of ergosterol and the increase of intermediate compounds alter fungal membrane integrity as well as cell morphology, which inhibits fungal growth.24, 25

Triazoles are among the most common systemic fungicides used in the control of plant diseases. Triazoles are absorbed and translocated in the plant, where they act preventively (before infection) or curatively (in the presence of symptoms) by affecting germ tube and appressoria formation or haustoria development and/or mycelial growth.26, 27 By widening the window of protection beyond protectant fungicides, which act only preventatively and are not translocated, the advantages of triazoles represent a breakthrough in increasing the productivity of various crops affected by fungal diseases.2 Around a third of all fungicides used for the protection of crop yields include triazoles, among which more than 99% are inhibitors of demethylation (DMI).28 However, triazole fungicides are also known to present long-term stability, allowing them to remain active in certain ecological niches, such as soil and water, for several months.2, 29

The number of antifungals available in the medical field for the treatment of systemic infections is relatively limited compared to those used for controlling diseases in plants, which is mainly due to problems related to erratic efficacy, drug toxicity, and intrinsic resistance.30 These compounds are usually effective in both topical and prophylactic treatments of invasive fungal infections.31 However, new triazoles that are less toxic to humans and with more specific targets have been investigated.32, 33, 34 The first generation of triazoles for human therapy included itraconazole and fluconazole. The second generation is represented by voriconazole and posaconazole, which proved to be less toxic, safer, and with a broader spectrum of activity, including activity against fungi that were resistant to the previous generation.35, 36 Presently, isavuconazole, ravuconazole, and albaconazole are being investigated in phase III clinical trials as extended-spectrum triazoles with fungicidal activity against a wide number of clinically important fungi.

Development and monitoring of triazole resistance

The development of resistance to triazoles as a result of selective pressure by the continued use of regular or sub-regular dosages of fungicide is typically quantitative and expressed by a gradual change in the frequency of resistant isolates.10 The main mechanisms involved have been reviewed and relate to the overexpression of the CYP51 gene due to mutations (insertions or duplications) in the promoter region and an increase in molecular efflux by ABC transporters caused by the overexpression of genes coding for membrane transport.9, 37, 38 Recently, a study that examined A. fumigatus isolates from a range of clinical environments suggested point mutations of CYP51 and TR34/L98H genomic regions in isolates obtained from patients with long term use of triazole-based therapy for the treatment of chronic aspergillosis.16

A key element in the sustainable use of fungicides is to monitor the sensitivity of the pathogen population to a certain compound.39, 40, 41 There are a number of direct and indirect methods recommended for specific fungi that are aimed at estimating the EC50 (effective concentration at which 50% of fungal growth is inhibited) and MIC (minimum inhibitory concentration) values.10, 42, 43, 44, 45

In the medical field, the surveillance and prevention of resistance to antifungal agents have been subject to many restrictive actions in recent years. More specifically, the FDA (Food and Drug Administration) and the EMA (European Medicines Agency) regulate and approve the use of antimicrobials in North America and Europe, respectively.46 Simultaneously, the Clinical and Laboratory Standards Institute (CLSI), together with the Subcommittee on Antifungal Susceptibility Testing (AFST) of the European Committee for Antimicrobial Susceptibility Testing (EUCAST), publish in vitro test protocols periodically for monitoring fungi sensibility to antifungal agents of clinical and veterinary use. These actions allow for the standardization of parameters for the evaluation of in vitro resistance in the laboratory. However, these actions and protocols do not involve the monitoring of resistance of plant pathogenic fungi, thus challenging the use of antifungal agents in clinical therapy.

In agriculture, the Fungicide Resistance Action Committee (FRAC), a technical group maintained by the industry, provides guidelines for the management of fungicide resistance, such as the need to estimate a baseline resistance level in isolates sampled from the population prior to the commercial use of a fungicide.47 During commercial use, reports of failures in disease control and detection of resistant isolates (those with sensitivity levels lower than the baseline) are indicators of the risk of developing fungicide resistance.47 Periodically, information is provided by the FRAC about the risk of plant pathogens that ranges from low to high. Currently, many studies are known that report steadily increasing resistance to triazoles in plant pathogenic fungi.48

Triazole resistance in clinical isolates and agricultural use

In the medical field, the first report of DMI's resistance in A. fumigatus isolates dates back more than three decades ago. However, the resistance to itraconazole by Aspergillus spp. from the clinical environment was first reported in 1997 for three isolates obtained from California in the late 1980s.49 The prescription of triazoles as a preferential choice for the treatment of patients with respiratory diseases has been considered to contribute to the development of resistance to this group of fungicides.10, 50, 51 Multidrug-resistance (MDR)52 is considered to be the cause of the failure of a wide range of antifungal agents available on the market.53, 54 As an emergent fungus in clinical environments, A. fumigatus holds a history of cross-resistance and multi-resistance to azoles.55 It is probable that millions of people are not effectively treated due to infections by fungi exhibiting antifungal resistance, among which 4.8 million cases are related only to the species of Aspergillus.56 The triazole antifungals commonly used in the medical field for the treatment of fungal diseases and pathogens that have exhibited some level of resistance are listed in Table 1.

Table 1.

Pathogenic fungi with intrinsic or developed resistance to triazoles for human therapeutic use.

Triazole Fungi References
Itraconazole Aspergillus fumigatus; Fusarium solani; F. oxysporum; Zygomycetes; Candida spp. 83, 84, 85, 86, 87, 63
Fluconazole Candida spp.; Saccharomyces cerevisiae; Trichosporon spp.; Fusarium solani; F. oxysporum; Scedosporium spp.; Penicillium spp.; Bipolaris australiensis; B. hawaiiensis; B. spicifera; Aspergillus spp.; Dermatophytes; Zygomycetes; dimorphic fungi; Cryptococcus neoformans 73,84,85,88, 89, 90, 91, 92, 93
Voriconazole Aspergillus fumigatus; Zygomycetes Trichosporon spp.; Penicillium spp. 86,87,94,95
Posaconazole Aspergillus fumigatus 96
Ravuconazole Fusarium solani; F.oxysporum; Zygomycetes; Pseudallescheria spp.; Scedosporium spp.; Acremonium spp.; Sporothrix schenckii; Scopulariopsis spp.; Paecilomyces spp. 20,34
Albaconazole Fusarium solani; Zygomycetes 34
Isavuconazole Aspergillus fumigatus 97
Open in a new tab

It has been shown that exposure of environmental fungi to triazole fungicides may cause shifts from susceptible to resistant populations, especially in the absence of adaptive costs which may facilitate the spread of resistant populations into diverse environments.57 The surge of “emerging fungi” in the medical field or fungi that are otherwise harmless to humans, such as the zygomycetes and other hyaline filamentous fungi,2, 57 has led some authors to hypothesize that other mechanisms may be leading to resistance, such as the large amount of fungicides used in agroecosystems.7, 58, 59 This hypothesis was initially suggested by studies conducted in the Netherlands13 and later corroborated by studies conducted in Spain,60 Belgium,13 Norway,13 Great Britain,61 Denmark,62 France,63 China,64 Italy,65 Austria,65 and India.28

A few studies have jointly examined the sensitivity of isolates that cause diseases in both plants and humans to triazoles. These studies suggested that the selection of fungicides with a similar mode of action as those used in human drug therapy for triazole-resistant isolates could contribute to the development of multi-resistant populations.66, 67 The development of cross-resistance to triazoles and the low number of triazoles recommended for human therapy relative to the high number of triazoles used in agriculture may affect triazole efficacy for human therapy.6, 10 For instance, the fungus Colletotrichum graminicola that causes anthracnose of corn plants is an emerging pathogen in humans. Resistance to tebuconazole as well as to multiple other azole antifungals has been reported in plant pathogenic populations used in clinical medicine.68, 69 Similarly, cross-resistance to triazoles was observed in clinical isolates of Candida albicans and agricultural environmental yeasts.70

Several other fungi have been found in association with human and animal diseases, including species of several genera such as Bipolaris, Macrophomina, Aspergillus, Fusarium, Alternaria and Mucor18, 71, 72, 73 (Table 2). The pathogenicity of clinical isolates of the Fusarium solani species complex was confirmed in plants of the Cucurbitacea family, which exhibited similar aggressiveness to isolates originating from diseased plants.17 Criptococcus neoformans is also found in different environmental niches, such as plants and animals.74 Fluconazole is the most prevalent clinical antifungal used to treat cryptococcosis.75 However, the continued use of this antifungal is an increasing concern due to the frequency of isolates resistant to triazoles used in human therapeutic use.76 There is a need for attention to azole resistance and optimal therapy in regions with high incidence of cryptococcosis, such as the Asian-Pacific region (5.1–22.6%), Africa/Middle-East (7.0–33.3%), and Europe (4.2–7.1%).77 In addition to fluconazole resistance in these regions, the new point of mutation in the ERG11 gene of C. neoformans afforded resistance to voriconazole (VRC).78 In these cases, the spread of isolates exhibiting resistance to triazoles into the environment and those capable of causing human diseases may affect the efficacy of therapeutic control with fungicides of the same group, especially in the presence of cross-resistance.79

Table 2.

Main genera of fungi reported as the causative agents of diseases in plants and in humans.

Genus Species References
Fusarium F. dimerum; F. verticilliodies; F. solani; F. oxysporium; F. gramminearum; F. poae; F. sporotrichoides; F. culmorum 18,98,99
Alternaria A. alternate 100,101
Aspergillus A. flavus; A. par
B. asiticus; A. terreus 		18,98,102, 103, 104
Curvularia C. lunata 105
Cladosporium C. cladosporioides 106,107
Colletotrichum C. gloeosporioides, C. coccodes 68,108
Mucor M. piriforms 109,110
Absidia Absidia spp. 18,109
Rhizopus R. arrizhus 109,111
Macrophomina M. phaseolina 72
Bipolaris B. australiensis; B. hawaiiensis; B. spicifera 73,112
Open in a new tab

The mutagenesis in TR34/L98H in azole-resistant Aspergillus may have originated due to the use of triazole fungicides in agroecosystems.14, 28, 80 Such mutation was detected in 89% of A. fumigatus-resistant isolates from air samples, flowers, and soils from hospital areas.6 Microsatellite sequencing of clinical and environmental isolates that lead to the TR34/L98H mutation revealed high genetic homology, which suggests a common ancestor.6, 13

Future directions

Triazole antifungals largely used in plant protection are also important as antifungal treatments in the human medical field even though they possessing structural differences. However, sensitive populations that co-inhabit environments may be reduced by the selection of isolates resistant to fungicides. Fungi arising from agricultural ecosystems as opportunistic pathogens may carry cross-resistance to triazoles used in the medical field. The restricted number of antifungal agents for clinical use, which contrasts with the large number of agricultural fungicides with similar modes of action, may be a risk factor that limits the success of the therapeutic use of these drugs.

Currently, genome-wide studies, together with novel T-cell-based therapeutic approaches for the prophylaxis and treatment of opportunistic fungal infections, have promising avenues of research in the detection of potentially new antifungal targets.81, 82 Thus, different strategies should be the main goals of the pharmaceutical industry.

Given that the search for new antifungal drugs is a lengthy process, the combination of drugs to achieve synergistic effects is currently adopted as an alternative. This approach includes the combination of drugs with distinct mechanisms of action that may enhance efficacy by combining low concentrations of both antifungal agents, thus diminishing the risk of developing resistance.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

The authors are thankful to the Coordenação de Aperfeiçoamento de Pessoal de nível superior – CAPES for financial support. A.M. Fuentefria and H.S. Schrekker are grateful to CNPq for the PQ fellowships.

Associate Editor: Carlos Pelleschi Taborda

References

  • 1.Horsfall J.G. Fungi and fungicides. The story of a nonconformist. Annu Rev Phytopathol. 1975;13:1–14. doi: 10.1146/annurev.py.13.090175.000245. [DOI] [PubMed] [Google Scholar]
  • 2.Hof H. Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother. 2001;45:2987–2990. doi: 10.1128/AAC.45.11.2987-2990.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Russel P.E. A century of fungicide evolution. J Agric Sci. 2005;143:11–25. [Google Scholar]
  • 4.Dehne H.W., Deising H.B., Gisi U., Kuck K.H., Russell P.E., Lyr H. Modern. Fungicides and antifungal compounds. International Reinhardsbrunn Symposium Friedrichroda, Vol. 15; Germany; 2007. pp. 45–51. [Google Scholar]
  • 5.Salam K.P., Tomas J.G., Beard C., Loughman R., Mac Leod W.J., Salam M.U. Application of meta-analysis in plant pathology: a case study examining the impact of fungicides on wheat yield loss from the yellow spot-septoria nodorum blotch disease complex in Western Australia. Food Secur. 2013;5:319–325. [Google Scholar]
  • 6.Snelders E., Huis In’t Veld R.A., Rijs A.J., Kema G.H., Melchers W.J., Verweij P.E. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053–4057. doi: 10.1128/AEM.00231-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Brown G.D., Denning D.W., Levitz S.M. Tackling human fungal infections. Science. 2012;336:647. doi: 10.1126/science.1222236. [DOI] [PubMed] [Google Scholar]
  • 8.Cools H.J., Fraaije B.A. Update on mechanisms of azole resistance in Mycosphaerella graminicola and implications for future control. Pest Manage Sci. 2013;69:150–155. doi: 10.1002/ps.3348. [DOI] [PubMed] [Google Scholar]
  • 9.Ma Z., Michailides T.J. Advances in understanding molecular mechanisms of fungicide resistance and molecular detection of resistant genotypes in phytopathogenic fungi. Crop Prot. 2005;24:853–863. [Google Scholar]
  • 10.Deising H.B., Reimann S., Pascholati S.F. Mechanisms and significance of fungicide resistance. Braz J Microbiol. 2008;39:286–295. doi: 10.1590/S1517-838220080002000017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.McGrath M.T. Fungicide resistance in cucurbit powdery mildew: experiences and challenges. Plant Dis. 2001;85:237–245. doi: 10.1094/PDIS.2001.85.3.236. [DOI] [PubMed] [Google Scholar]
  • 12.Denning D.W., Park S., Lass-Florl C. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–1129. doi: 10.1093/cid/cir179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Snelders E., van der Lee H.A., Kuijpers J., Rijs A.J.M.M., Varga J. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLOS Med. 2008;5:1629–1637. doi: 10.1371/journal.pmed.0050219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Snelders E., Camps S.M., Karawajczyk A. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE. 2012;7:e31801. doi: 10.1371/journal.pone.0031801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bowyer P., Denning D.W. Environmental fungicides and triazole resistance in Aspergillus. Pest Manage Sci. 2013;70:173–178. doi: 10.1002/ps.3567. [DOI] [PubMed] [Google Scholar]
  • 16.Lelièvre L., Groh M., Angebault C., Maherault A.C., Didier E., Bougnoux M.E. Azole resistant Aspergillus fumigatus: an emerging problem. Med Mal Infect. 2013;43:139–145. doi: 10.1016/j.medmal.2013.02.010. [DOI] [PubMed] [Google Scholar]
  • 17.Mehl H.L., Epstein L. Fusarium solani species complex isolates conspecific with F. solani f. s: cucurbitae race 2 from naturally infected human and plant tissue and environmental sources are equally virulent on plants, grow at 37 °C and are interfertile. Environ Microbiol. 2007;9:2189–2199. doi: 10.1111/j.1462-2920.2007.01333.x. [DOI] [PubMed] [Google Scholar]
  • 18.De Lucca A.J. Harmful fungi in both Agriculture and Medicine. Rev Iberoam Micol. 2007;24:3–13. [PubMed] [Google Scholar]
  • 19.Kaur S., Dhillon G.S., Brar S.K., Vallad E.G., Chand R., Chauhan B.V. Emerging phytopathogen Macrophomina phaseolina: biology, economic importance and current diagnostic trends. Crit Rev Microbiol. 2012;38:136–151. doi: 10.3109/1040841X.2011.640977. [DOI] [PubMed] [Google Scholar]
  • 20.Catalán M., Montejo J.C. Antifúngicos sistêmicos. Farmacodinâmica Y Farmacocinética. Rev Iberoam Micol. 2006;23:39–49. doi: 10.1016/s1130-1406(06)70012-2. [DOI] [PubMed] [Google Scholar]
  • 21.Sheppard D., Lampires H.W. Agentes antifúngicos. In: Katzung B.G., editor. Farmacologia Básica e Cínica. McGraw Hill Interamericana do Brasil, Guanabara Koogan; Rio de Janeiro, Brazil: 2008. pp. 707–714. [Google Scholar]
  • 22.Brent K.J. Global Crop Protection Federation; Brussels: 1995. Fungicide Resistance in Crop Pathogens, How Can it be Managed. [Google Scholar]
  • 23.Becher R., Wirsel S.G.R. Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens. Appl Microbiol Biotechnol. 2012;95:825–840. doi: 10.1007/s00253-012-4195-9. [DOI] [PubMed] [Google Scholar]
  • 24.Becher R., Hettwer U., Karlovsky P., Deising H.B., Wirsel S.G.R. Adaptation of Fusarium graminearum to tebuconazole yielded descendants diverging for levels of fitness, fungicide resistance, virulence, and mycotoxin production. Phytopathology. 2010;100:444–453. doi: 10.1094/PHYTO-100-5-0444. [DOI] [PubMed] [Google Scholar]
  • 25.Serfling S., Ordon F. Virulence and toxin synthesis of an azole insensitive Fusarium culmorum strain in wheat cultivars with different levels of resistance to Fusarium head blight (FHB) Plant Pathol. 2014;63:1230–1240. [Google Scholar]
  • 26.Buchenauer H. Mechanism of action of triazolyl fungicides and related compounds. In: Lyr H., editor. Modern Selective Fungicides: Properties, Applications, Mechanisms of Action. Longman Scientific and Technical; Harlow, United Kingdom: 1987. pp. 205–231. [Google Scholar]
  • 27.Pontzen R., Scheinpflug H. Effects of triazole fungicides on sterol biosynthesis during spore germination of Botrytis cinerea, Venturia inaequalis and Puccinia graminis f s: tritici. Netherlands. J Plant Pathol. 1989;95:151–160. [Google Scholar]
  • 28.Chowdhary A., Kathuria S., Randhawa H.S., Gaur S.N., Klaassen C.H. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67:362–366. doi: 10.1093/jac/dkr443. [DOI] [PubMed] [Google Scholar]
  • 29.Hamey P.Y., Harris C.A. The variation of pesticide residues in fruits and vegetables and the associated assessment of risk. Regul Toxicol Pharmacol. 1999;30:34–41. doi: 10.1006/rtph.1999.1324. [DOI] [PubMed] [Google Scholar]
  • 30.Bergold A.M., Georgiadis S. Novidades em fármacos antifúngicos: uma revisão new antifungic drugs: a review. Visão Acad. 2004;5:159–172. [Google Scholar]
  • 31.Hay R. Antifungal drugs. In: Katsambas A., Lotti T., editors. European Handbook of Dermatological Treatments. Springer; Berlin, Germany: 2003. pp. 700–710. [Google Scholar]
  • 32.Carrillo-Munõz A.J., Giusiano G., Ezcurra P.A., Quindóz G. Antifungal agents: mode of action yeast's cell. Rev Esp Quimioter. 2006;19:130–139. [PubMed] [Google Scholar]
  • 33.Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs. 2009;18:1279–1295. doi: 10.1517/13543780903176407. [DOI] [PubMed] [Google Scholar]
  • 34.Pasqualotto A.C., Thiele K.O., Goldani L.Z. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs. 2010;11:165–174. [PubMed] [Google Scholar]
  • 35.Thompson G.R., Cadena J., Patterson T.F. Overview of antifungal agents. Clin Chest Med. 2009;30:203–215. doi: 10.1016/j.ccm.2009.02.001. [DOI] [PubMed] [Google Scholar]
  • 36.Vandeputte V., Ferrari S., Coste A.T. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;713687:1–26. doi: 10.1155/2012/713687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Coleman J.J., Mylonakis E. Efflux in fungi: la pièce de résistance. PLoS ONE. 2009;5:1–7. doi: 10.1371/journal.ppat.1000486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ammar G.A., Tryono R., Do K., Karlovsky P., Deising H.B., Wirsel S.G.R. Identification of ABC transporter genes of Fusarium graminearum with roles in azole tolerance and/or virulence. PLoS ONE. 2013;8:2–13. doi: 10.1371/journal.pone.0079042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Parnell S., van den Bosch F., Gilligan C.A. Large-scale fungicide spray heterogeneity and the regional spread of resistant pathogen strains. Phytopathology. 2006;96:549–555. doi: 10.1094/PHYTO-96-0549. [DOI] [PubMed] [Google Scholar]
  • 40.Suzuki F., Yamaguchi J., Koba A., Nakajima T., Arai M. Changes in fungicide resistance frequency and population structure of Pyricularia oryzae after discontinuance of MBI-D fungicides. Plant Dis. 2010;94:329–334. doi: 10.1094/PDIS-94-3-0329. [DOI] [PubMed] [Google Scholar]
  • 41.Van der Heyden H., Dutilleul P., Brodeur L., Carisse O. Spatial distribution of single nucleotide polymorphisms related to fungicide resistance and implications for sampling. Phytopathology. 2014;104:604–613. doi: 10.1094/PHYTO-03-13-0085-R. [DOI] [PubMed] [Google Scholar]
  • 42.Edgington L.V., Khnw K.L., Barron G.L. Fungitoxic spectrum of benzimidazole compounds. Phytopathology. 1971;61:42–44. [PubMed] [Google Scholar]
  • 43.Liu X., Yin Y., Wu J., Jiang J., Ma Z. Identification and characterization of carbendazim-resistant isolates of Gibberella zeae. Plant Dis. 2010;94:1137–1142. doi: 10.1094/PDIS-94-9-1137. [DOI] [PubMed] [Google Scholar]
  • 44.Spolti P., Jorge B.C., Del Ponte E.M. Sensitivity of Fusarium graminearum causing head blight of wheat in Brazil to tebuconazole and metconazole fungicides. Trop Plant Pathol. 2012;37:419–423. [Google Scholar]
  • 45.Spolti P., Del Ponte E.M., Dong Y., Cummings J.A., Bergstrom G.C. Triazole sensitivity in a contemporary population of Fusarium graminearum from New York wheat and competitiveness of a tebuconazole-resistant isolate. Plant Dis. 2014;98:607–613. doi: 10.1094/PDIS-10-13-1051-RE. [DOI] [PubMed] [Google Scholar]
  • 46.Aparicio J.F., Mendes M.V., Antón N., Recio E., Martín J.F. Polyenemacrolide antiobiotic biosynthesis. Curr Med Chem. 2004;1:645–1656. doi: 10.2174/0929867043365044. [DOI] [PubMed] [Google Scholar]
  • 47.Brent K.J., Hollomon D.W. Fungicide resistance in crop pathogens: how can it be managed? FRAC Monograph n.1. 2007 [Google Scholar]
  • 48.FRAC. FRAC cod list. FRAC information: list of resistance. Available in: http://www.frac.brasil.org.br (accessed 05.05.15).
  • 49.Denning D.W., Venkateswarlu K., Oakley K.L., Anderson M.J., Manning P.J., Stevens D.A. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents. 1997;41:1364–1368. doi: 10.1128/aac.41.6.1364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Shao P.L., Huang L.M., Hsueh P.R. Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents. 2007;6:487–495. doi: 10.1016/j.ijantimicag.2007.07.019. [DOI] [PubMed] [Google Scholar]
  • 51.Gore R.B. The utility of antifungal agents asthma. Curr Opin Pulm Med. 2010;16:36–41. doi: 10.1097/MCP.0b013e328333900a. [DOI] [PubMed] [Google Scholar]
  • 52.Gulshan K., Moye-Rowley W.S. Multidrug resistance in fungi. Eukaryot Cell. 2007;6:1933–1942. doi: 10.1128/EC.00254-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science. 2009;325:1089–1093. doi: 10.1126/science.1176667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida sp.: by use of clinical and laboratory standards institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–2856. doi: 10.1128/JCM.00937-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Howard S.J., Webster I., Moore C.B., Gardiner R.E., Park S., Perlin D.S. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents. 2006;28:450–453. doi: 10.1016/j.ijantimicag.2006.08.017. [DOI] [PubMed] [Google Scholar]
  • 56.Denning D., Pleuvry A., Cole D. Global burden of ABPA in adults with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51:361–370. doi: 10.3109/13693786.2012.738312. [DOI] [PubMed] [Google Scholar]
  • 57.Verweij E., Kema G.H., Zwaan B., Melchers W.J. Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manage Sci. 2013;69:165–170. doi: 10.1002/ps.3390. [DOI] [PubMed] [Google Scholar]
  • 58.Ruping M.J.G.T., Vehreschil J.J., Cornely O.A. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008;68:1941–1962. doi: 10.2165/00003495-200868140-00002. [DOI] [PubMed] [Google Scholar]
  • 59.Tobudic S., Kratzer C., Presterl E. Azole-resistant Candida sp.: emerging pathogens. Mycoses. 2012;55:24–32. [Google Scholar]
  • 60.Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Monzon A., Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigates. Antimicrob Agents Chemother. 2008;52:2468–2472. doi: 10.1128/AAC.00156-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Howard S.J., Pasqualotto A.C., Denning D.W. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect. 2010;16:683–688. doi: 10.1111/j.1469-0691.2009.02911.x. [DOI] [PubMed] [Google Scholar]
  • 62.Mortensen K.L., Mellado E., Lass-Flörl C., Rodriguez-Tudela J.L., Johansen H.K. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. 2010;54:4545–4549. doi: 10.1128/AAC.00692-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Burgel P.R., Baixench M.T., Amsellem M., Audureau E., Chapron J., Kanaan R. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother. 2012;56:869–874. doi: 10.1128/AAC.05077-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Lockhart S.R., Frade J.P., Etienne K.A., Pfaller M.A., Diekema D.J., Balajee S.A. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55:4465–4468. doi: 10.1128/AAC.00185-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Van der Linden J.W., Arendrup M.C., Verweij P.E. ICAAC; Chicago, USA: 2011. SCARE-Network. Prospective International Surveillance of Azole Resistance in Aspergillus fumigatus (SCARE-Network) [Google Scholar]
  • 66.Meneau I., Sanglard D. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol. 2005;43:307–311. doi: 10.1080/13693780500090826. [DOI] [PubMed] [Google Scholar]
  • 67.Drummond D.E., Reimão J.Q., Dias A.L.T., Siqueira A.M. Comportamento de mostras ambientais e clínicas de Cryptococcus neoformans frente a fungicidas de uso agronômico e ao fluconazol. Rev Soc Bras Med Trop. 2007;2:209–211. doi: 10.1590/s0037-86822007000200012. [DOI] [PubMed] [Google Scholar]
  • 68.O’Quinn R.P., Hoffman J.L., Boyd A.S. Colletotrichum species as emerging opportunistic fungal pathogens: a report of 3 cases of phaeohyphomycosis and review. J Am Acad Dermatol. 2001;l45:56–61. doi: 10.1067/mjd.2000.113691. [DOI] [PubMed] [Google Scholar]
  • 69.Serfling A., Wohlrab J., Deising H.B. Treatment of a clinically relevant plant pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy. Antimicrob Agents Chemother. 2007;51:3672–3676. doi: 10.1128/AAC.00654-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Müller F.M., Staudigel A., Salvenmoser S., Tredup A., Miltenberger R., Herrmann J.V. Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes. Antimicrob Agents Chemother. 2007;51:3014–3016. doi: 10.1128/AAC.00459-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Mehanna H.M., Kuo T., Chaplin J., Taylor G., Morton R.P. Fungal laryngitis in immunocompetent patients. J Laryngol Otol. 2004;118:379–381. doi: 10.1258/002221504323086615. [DOI] [PubMed] [Google Scholar]
  • 72.Srinivasan A., Wickes B.L., Romanelli A.M., Debelenko L., Rubnitz J.E. Cutaneous Infection caused by Macrophomina phaseolina in a child with acute myeloid leukemia. J Clin Microbiol. 2009;47:1969–1972. doi: 10.1128/JCM.02397-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Cunha K.C., Sutton D.A., Fothergill A.W. Diversity of Bipolaris species in clinical samples in the United States and their antifungal susceptibility profiles. J Clin Microbiol. 2012;50:4061–4066. doi: 10.1128/JCM.01965-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Chowdhary A., Randhawa H.S., Sundar G. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol. 2011;60:961–967. doi: 10.1099/jmm.0.029025-0. [DOI] [PubMed] [Google Scholar]
  • 75.Gullo F.P., Rossi S.A., Sardi Jde C., Teodoro V.L., Mendes-Giannini M.J., Fusco-Almeida A.M. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis. 2013;32:1377–1391. doi: 10.1007/s10096-013-1915-8. [DOI] [PubMed] [Google Scholar]
  • 76.Paul S., Doering T.L., Moye-Rowley W.S. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance. Fungal Genet Biol. 2015;74:1–9. doi: 10.1016/j.fgb.2014.10.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Pfaller M.A., Diekema D.J., Gibbs D.L. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009;47:117–123. doi: 10.1128/JCM.01747-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Sionov E., Lee H., Chang Y.C., Kwon-Chung K.J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6:1–13. doi: 10.1371/journal.ppat.1000848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Williams D.A., Lemke T.L. 5a ed. Philadelphia, Lippincot Williams and Wilkins; New Jersey, USA: 2002. Foye's Principles of Medicinal Chemistry. [Google Scholar]
  • 80.Singh P.K., Gaur S.N., Hagen F. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053–4057. doi: 10.1128/AEM.00231-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Barrera A., Alastruey-Izquierdo A., Martín M.J., Cuesta I., Vizcaíno J.A. Analysis of the protein domain and domain architecture content in fungi and its application in the search of new antifungal targets. PLoS Comput Biol. 2014;10:1–16. doi: 10.1371/journal.pcbi.1003733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Mancini N., Marrone L., Clementi N., Sautto G.A., Clementi M., Burioni R. Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections. Future Microbiol. 2015;10:665–682. doi: 10.2217/fmb.14.122. [DOI] [PubMed] [Google Scholar]
  • 83.Alastruey-Izquierdo A., Cuenca-Estrella M., Monzón, Emilia Mellado A., Rodríguez-Tudela J.L. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother. 2008;61:805–809. doi: 10.1093/jac/dkn022. [DOI] [PubMed] [Google Scholar]
  • 84.Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fisher M.C. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15:1068–1076. doi: 10.3201/eid1507.090043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Almeida L.M.M., Souza E.A.F., Bianchin D.B., Svidzinski T.I.E. Resposta in vitro de fungos agentes de micoses cutâneas frente aos antifúngicos sistêmicos mais utilizados na dermatologia. An Bras Dermatol. 2009;84:249–255. doi: 10.1590/s0365-05962009000300006. [DOI] [PubMed] [Google Scholar]
  • 86.Beernaert L.A., Pasmans F., Van Waeyenberghe L. Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole. Antimicrob Agents Chemother. 2009;53:2199–2201. doi: 10.1128/AAC.01492-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Dota K.F.D., Freitas A.R., Consolaro M.E.L., Svidzinski T.I.E. A challenge for clinical laboratories: detection of antifungal resistance in Candida species causing vulvovaginal candidiasis. Lab Med. 2011;42:87–93. [Google Scholar]
  • 88.Sanguinetti M., Posteraro B., Fiori B., Ranno S., Torelli R., Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2015;49:668–679. doi: 10.1128/AAC.49.2.668-679.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Quintero C.H.G. Resistencia de levaduras del género Candida al fluconazol Candida yeast's resistance to fluconazol. Infectio. 2010;14:172–180. [Google Scholar]
  • 90.Cheong J.W., McCormack J. Fluconazole resistance in cryptococcal disease: emerging or intrinsic. Med Mycol. 2013;51:261–269. doi: 10.3109/13693786.2012.715763. [DOI] [PubMed] [Google Scholar]
  • 91.Adimi P., Hashemi S.J., Mahmoudi M. In-vitro activity of 10 antifungal agents against 320 dermatophyte strains using microdilution method in Tehran. IJPR. 2013;12:537–545. [PMC free article] [PubMed] [Google Scholar]
  • 92.Wang J.F., Xue Y., Zhu X.B., Fan H. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. Eur J Clin Microbiol Infect Dis. 2015;34:651–659. doi: 10.1007/s10096-014-2287-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Hashemi S.M., Badali H., Faramarzi M.A. Novel triazole alcohol antifungals derived from fluconazole: design, synthesis, and biological activity. Mol Divers. 2015;19:15–27. doi: 10.1007/s11030-014-9548-0. [DOI] [PubMed] [Google Scholar]
  • 94.Van der Linden J.W., Jansen R.R., Bresters D. Azole-resistant central nervous system aspergillosis. Clin Infect Dis. 2009;48:1111–1113. doi: 10.1086/597465. [DOI] [PubMed] [Google Scholar]
  • 95.Chowdhary A., Kathuria S., Agarwal K. Voriconazole-resistant Penicillium oxalicum: an emerging pathogen in immunocompromised hosts. Open Forum Infect Dis. 2014;1:1–7. doi: 10.1093/ofid/ofu029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Choukri F., Botterel F., Sitterlé E. Prospective evaluation of azole resistance in Aspergillus fumigatus clinical isolates in France. Med Mycol. 2015;53:593–596. doi: 10.1093/mmy/myv029. [DOI] [PubMed] [Google Scholar]
  • 97.Gregson L., Goodwin J., Johnson A. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother. 2013;57:5778–5780. doi: 10.1128/AAC.01141-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Naiker S., Odhav B. Mycotic keratitis: profile of Fusarium species and their mycotoxins. Mycoses. 2004;47:50–56. doi: 10.1046/j.0933-7407.2003.00936.x. [DOI] [PubMed] [Google Scholar]
  • 99.Mehl H.L., Epstein L. Sewage and community shower drains are environmental reservoirs of Fusarium solani species complex group 1, a human and plant pathogen. Environ Microbiol. 2008;10:219–227. doi: 10.1111/j.1462-2920.2007.01446.x. [DOI] [PubMed] [Google Scholar]
  • 100.Brandt M.E., Warnock D.W. Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi. J Chemother. 2003;2:36–47. doi: 10.1179/joc.2003.15.Supplement-2.36. [DOI] [PubMed] [Google Scholar]
  • 101.Chhabra V., Rastogi S., Barua M., Kumar S. Alternaria alternata infection associated osteomyelitis of maxilla: a rare disease entity. Indian J Dent Res. 2013;24:639–641. doi: 10.4103/0970-9290.123420. [DOI] [PubMed] [Google Scholar]
  • 102.Diener U.L., Cole R.J., Sanders T.H., Payne G.A., Lee L.S., Klich M.A. Epidemiology of aflatoxin formation by Aspergillus flavus. Annu Rev Phytopathol. 1987;25:249–270. [Google Scholar]
  • 103.Abbas H.K., Williams W.P., Windham G.L., Pringle C.H., Xie W., Shier W.T. Aflatoxin and fumonisin contamination of commercial corn (Zea mays) hybrids in Mississippi. J Agric Food Chem. 2002;50:5246–5254. doi: 10.1021/jf020266k. [DOI] [PubMed] [Google Scholar]
  • 104.Lass-Florl C., Mayr A., Perkhofer S. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2008;52:3637–3641. doi: 10.1128/AAC.00662-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Navi S.S., Bandyopadhyay R., Reddy R.K., Thakur R.P., Yang X.B. Effects of wetness duration and grain development stages on sorghum grain mold infection. Plant Dis. 2005;89:872–878. doi: 10.1094/PD-89-0872. [DOI] [PubMed] [Google Scholar]
  • 106.Tournas V.H. Spoliage of the vegetable crops by bacteria and fungi and related health hazards. Crit Rev Microbiol. 2005;31:33–44. doi: 10.1080/10408410590886024. [DOI] [PubMed] [Google Scholar]
  • 107.Weikl F., Radl V., Munch J.C., Pritsch K. Targeting allergenic fungi in agricultural environments aids the identification of major sources and potential risks for human health. Sci Total Environ. 2015;25:223–230. doi: 10.1016/j.scitotenv.2015.05.056. [DOI] [PubMed] [Google Scholar]
  • 108.Cano J., Guarro J., Molecular Gené J. Morphological identification of Colletotrichum species of clinical interest. J Clin Microbiol. 2004;42:2450–2454. doi: 10.1128/JCM.42.6.2450-2454.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Kobayashi M., Hiruma M., Matsushita A., Kawai M., Ogawa H., Udagawa S. Cutaneous zygomycosis: a case report and review of Japanese reports. Mycoses. 2001;44:311–315. [PubMed] [Google Scholar]
  • 110.Miceli M.H., Lee S.A. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses. 2011;54:666–678. doi: 10.1111/j.1439-0507.2011.02032.x. [DOI] [PubMed] [Google Scholar]
  • 111.Cornely O.A. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection. 2008;6:296–313. doi: 10.1007/s15010-008-7357-z. [DOI] [PubMed] [Google Scholar]
  • 112.El Khizzi N., Bakheshwain S., Bipolaris Parvez S. A plant pathogen causing human infections: an emerging problem in Saudi Arabia. Res J Microbiol. 2010;5:212–217. [Google Scholar]

Articles from Brazilian Journal of Microbiology are provided here courtesy of Brazilian Society of Microbiology

RESOURCES